Skip to content

Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein

Choice of the Optimal Method for Treatment of Acute Thrombophlebitis of the Varicose Great Saphenous Vein: Comparison of Endovenous Laser Ablation and Conservative Approach

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05001776
Enrollment
105
Registered
2021-08-12
Start date
2021-08-16
Completion date
2023-12-01
Last updated
2023-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial Vein Thrombosis, Endovenous Laser Ablation

Keywords

acute thrombophlebitis, acute thrombosis, superficial vein of leg, great saphenous vein, various vein, endovenous laser ablation, fondaparinux

Brief summary

Рrospective single-centre randomized open-label study for comparison three modes of treatment for thrombosis of varicose great saphena vein - standard medical with fondaparinux sodium for 45 days, endovenous laser ablation close to the saphenofemoral junction with a 7-day course of anticoagulation and endovenous laser ablation close to the saphenofemoral junction without the use of anticoagulants.

Detailed description

Superficial venous thrombosis is a common complication in patients with varicose veins of low extremities. The most dangerous consequence of such thrombosis is its propagation to deep veins and subsequent pulmonary embolism. Recommended mode of treatment for superficial vein thrombosis is a prolonged usage of anticoagulants (preferably fondaparinux sodium for least 45 days as the best-studied approach). However, it may be not suitable for some patients, for example with a high risk of bleeding. Another possible mode of treatment is endovenous laser ablation of the saphenous vein very close to the saphenofemoral junction. This a minimally invasive procedure that may be performed ambulatory is able to decrease the risk of deep veins thrombosis and possibly allow to shorten or even eliminate the necessity of anticoagulant use. Such a suggestion was not appropriately studied in randomized clinical trials. The aim of this prospective single-centre randomized open-label study is to compare three modes of treatment for thrombosis of varicose great saphena vein - standard medical with fondaparinux sodium, endovenous laser ablation close to the saphenofemoral junction with shortening the course of anticoagulation and endovenous laser ablation close to the saphenofemoral junction without the use of anticoagulants.

Interventions

Laser ablation of the great saphenous vein close to sapheno-femoral junction

Fondaparinux sodium for 7 days or 45 days

Sponsors

National Medical Research Center for Therapy and Preventive Medicine
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective single-centre open-label randomized

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or more * Acute thrombosis of varicose great saphenous vein and/or its major branches more than 5 cm from the saphenofemoral junction * Signed informed consent

Exclusion criteria

* More than 3 weeks after symptom onset * Ultrasound signs of deep vein thrombosis * Suspected pulmonary embolism * Superficial vein thrombosis within 5 cm from the saphenofemoral junction * Bilateral superficial vein thrombosis * Thrombosis of subfascial part of perforating veins to the level of fascia * Thrombosis of small saphenous vein * Superficial vein thrombosis associated with sclerotherapy * History of deep vein thrombosis and/or pulmonary embolism * Superficial vein thrombosis within 3 months before inclusion * Anemia (haemoglobin less than 90 g/l) * Low platelet count (less than 100 X 109/l) * Severe renal impairment (calculated GFR less than 20 ml/min/1,73 m2) * Body mass less than 50 kg * Morbid obesity (BMI higher than 40 kg/m2) * Allergy to fondaparinux sodium and local anaesthetics * Using anticoagulants for treating the current episode of venous thrombosis * Using anticoagulants for other medical conditions (e.g. atrial fibrillation) * Double antiplatelet therapy * Regular use of NSAIDs (except aspirin less than 325 mg daily) * High risk of bleeding according to an investigator * Active clinically relevant bleeding * Clinically relevant bleeding within last 30 days before inclusion * Major surgery of severe head trauma within last 30 days before inclusion * Ophthalmic, spinal or cerebral surgery within last 12 months * Active gastric or duodenum ulcer, erosive and ulcerative gastrointestinal disorder * Documented haemorrhagic diathesis * Uncontrolled arterial hypertension (systolic\[180 mm Hg, diastolic\[110 mm Hg) * Active cancer, history of cancer * Acute illness, decompensation of chronic illness * Autoimmune disease, treatment of autoimmune disease * Severe chronic heart failure and/or marked oedema due to heart failure * Severe pulmonary insufficiency * Bacterial endocarditis * Severe renal failure * Known severe thrombophilia (antiphospholipid syndrome, a deficit of antithrombin, a deficit of protein C, S, factor V Leiden, prothrombin G20210A) * Immobility, unable to increase mobility * Pregnant or breastfeeding women * Alcohol abuse, drugs abuse or other circumstances indication low compliance * Unwilling of unable to follow requirements of the protocol

Design outcomes

Primary

MeasureTime frameDescription
Composite of deep vein thrombosis, symptomatic pulmonary embolism, superficial vein thrombosis extension, superficial vein thrombosis recurrence or thrombosis of subfascial part of perforating veins to the level of fascia45 daysAll vein thrombosis should be confirmed by ultrasonography, pulmonary embolism - by computed tomography. Supreficial vein thrombosis extension - increasing size of existing thrombosis at least 2 cm. Superficial vein thrombosis recurrence - thrombosis of new superficial vein not related to index thrombosis or new thrombosis in the same superficial vein clearly separated from index thrombosis by segment on vein without signs of thrombosis at least 10 cm in length
Major bleedings45 daysMajor bleedings according to ISTH definition

Secondary

MeasureTime frameDescription
Composite of death, symptomatic deep vein thrombosis, symptomatic pulmonary embolism, symptomatic superficial vein thrombosis extension or symptomatic superficial vein thrombosis recurrence7 daysAll vein thrombosis should be confirmed by ultrasonography, pulmonary embolism - by computed tomography. Supreficial vein thrombosis extension - increasing size of existing thrombosis at least 2 cm. Superficial vein thrombosis recurrence - thrombosis of new superficial vein not related to index thrombosis or new thrombosis in the same superficial vein clearly separated from index thrombosis by segment on vein without signs of thrombosis at least 10 cm in length
Composite of deep vein thrombosis, symptomatic pulmonary embolism, superficial vein thrombosis extension, superficial vein thrombosis recurrence or thrombosis of subfascial part of perforating veins to the level of fascia7 daysAll vein thrombosis should be confirmed by ultrasonography, pulmonary embolism - by computed tomography. Supreficial vein thrombosis extension - increasing size of existing thrombosis at least 2 cm. Superficial vein thrombosis recurrence - thrombosis of new superficial vein not related to index thrombosis or new thrombosis in the same superficial vein clearly separated from index thrombosis by segment on vein without signs of thrombosis at least 10 cm in length
Major bleedings7 daysMajor bleedings according to ISTH definition
All bleedings7 daysAll overt bleedings classified as major, clinically relevant non-major and minor according to ISTH criteria
Bleedings according to BARC criteria7 daysOvert bleedings classified with BARC criteria

Other

MeasureTime frameDescription
Severity of pain7 days10 cm visual analog scale of pain and 0-10 numeric pain rating score (0 - no pain, 10 - worst imaginable pain)
Quality of life according to European Quality of Life Questionnaire EQ-5D-3L7 daysZero score is equivalent to no disability and a score of 10 is equivalent to maximal disability
Quality of life according to Chronic Venous Disease quality of life Questionnaire (CIVIQ-20)7 daysZero score is equivalent to maximum disability and a score of 100 is equivalent to no disability
Quality of life according to 36-Item Short Form Health Status Survey7 daysZero score is equivalent to maximum disability and a score of 100 is equivalent to no disability
Surgical intervention for superficial vein thrombosis45 daysRequirement of unplanned surgical intervention for treatment of superficial vein thrombosis

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026